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Modification of chromium(VI)-induced DNA damage by glutathione
and cytochromes P-450 in chicken embryo hepatocytes
(metal carcinogenesis/chromate metabolism/DNA strand breaks/DNA cross-links)

DOREEN Y. CUPO*t AND KAREN E. WETTERHAHN**
*Department of Chemistry, Dartmouth College, and tDepartment of Biochemistry, Dartmouth Medical School, Hanover, NH 03755

Communicated by Walter H. Stockmayer, June 17, 1985

ABSTRACT
The role of glutathione and cytochrome P-450
in the production of DNA damage by chromium(VI) was
examined In chicken embryo hepatocytes by the alkaline elution
technique. Cellular levels of glutathione and cytochrome P-450
were altered by treating the hepatocytes with N-acetyl-Lcysteine, buthionine sulfoximine, isopentanol, or 8-naphthoflavone. A dramatic increase in chromium(VI)-induced
DNA strand breaks was observed after increasing glutathione
levels in the cells. Chromium(VI)-induced DNA strand breaks
were even more numerous when the level of cytochrome P-450
was also increased. Upon depletion of glutathione levels and
induction of cytochrome P-450 or cytochrome P 448, little or no
DNA strand breaks or DNA interstrand cross-links were
observed after chromium(VI) treatment. Chromium(VI)-induced DNA-protein cross-links generally decreased after either
increases or decreases in cellular levels of glutathione or
cytochrome P-450 or P-448. These results suggest that
glutathione enhances chromium(VI)-induced DNA damage
through metabolic activation of chromium(VI). The possible
production of reactive chromium species upon metabolism by
glutathione and cytochrome P-450 or P448 and their involvement in DNA damage is discussed.

Chromium(VI) compounds are recognized as carcinogens in
humans and animals (1) and as mutagens in bacterial and
mammalian cell systems (2). Chromium(VI) causes DNA
strand breaks and cross-links in vivo and in cultured cells
(3-6). It has been proposed that cellular metabolism of
chromium(VI) compounds is necessary for DNA damage,
since chromium(VI) does not react with isolated DNA under
physiological conditions (7). The DNA-damaging ability of
other carcinogenic agents has been shown to be modulated by
metabolic pathways such as the cytochrome P450 system,
sulfotransferases, and glutathione (GSH) (8). Changes in
cellular levels of cytochromes P-450 alter the levels of DNA
damage produced by carbon tetrachloride (9), benzo[a]pyrene (10), and dimethylnitrosamine (11) in rodents.
In vitro studies have identified several cellular components
that are capable of metabolizing chromium(VI) (12-14). Rat
liver microsomes contain a NADPH-dependent chromium(VI) reductase activity (15). Induction of cytochrome(s)
P-450 by phenobarbital enhances the chromium(VI)
reductase activity of liver microsomes; however, induction of
cytochrome(s) P-448 by 3-methylcholanthrene has no effect
(13). GSH also reduced chromium(VI) in vitro under physiological conditions (12, 14). The reaction of GSH with
chromium(VI) has been proposed to occur by a two-step
mechanism that involves the rapid formation of a chromium(VI) thioester followed by the reduction of the chromium(VI) thioester to chromium(III) (12).
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.

The present report describes the effect of altering the

intracellular concentrations of cytochrome P450 and P-448
and GSH on chromium(VI)-induced DNA damage in primary
cultured chicken embryo hepatocytes. Chromium(VI) treatment is known to produce DNA damage in chicken embryo
hepatocytes (5, 6). The hepatocytes are well suited for these
experiments because intracellular levels of the different
isozymes of cytochrome P-450 can be increased by f
naphthoflavone (16) and isopentanol (17). GSH has been
shown to increase in these cells with the induction of
cytochrome P-450, but not with induction of cytochrome
P-448 (18). Also, GSH can be decreased in chicken embryo
hepatocytes by buthionine sulfoximine (18) or increased by
N-acetyl-L-cysteine (see below). The present report shows
that changes in cellular levels of cytochrome P-450 or P-448

and GSH in the hepatocytes resulted in dramatic alterations
of the levels and types of chromium(VI)-induced DNA
lesions detected by the alkaline elution technique.

MATERIALS AND METHODS
Chemicals. Williams E medium was purchased from Flow
Laboratories. Sodium [51Cr]chromate with a specific activity
of 0.5 mCi/pg (1 Ci = 37 GBq) was obtained from Amersham.
Buthionine sulfoximine was obtained from Chemalog (South
Plainfield, NJ). All other chemicals were purchased from
Fisher or Sigma.
Preparation and Treatment of Chicken Embryo Hepatocytes. Primary cultures of hepatocytes were prepared from
the livers of 16-day embryos and cultured as described
previously (5). Approximately 2 x 106 cells were seeded on
3.5-cm polystyrene tissue culture dishes for all experiments,
except for the spectral cytochrome P-450 assays, which
required approximately 4.4 x 106 cells on 6.0-cm dishes. The
medium was replaced with fresh medium 24 hr after the cells
had been plated. For all the chromium experiments, 48 hr
after the hepatocytes had been plated, the cells were exposed
to 5 AtM sodium chromate in the medium for 2 hr. Drug
pretreatments varied as follows: to increase GSH, hepatocytes were treated for 2 hr with 1 mM N-acetyl-L-cysteine
and then the N-acetyl-L-cysteine was removed and fresh
medium was added prior to chromate treatment; to decrease
GSH, cells were treated with 0.1 mM buthionine sulfoximine
for 20 hr before chromate addition; to increase cytochrome
P448, cells were treated with 15 ,uM P-naphthoflavone in the
presence or absence of 0.1 mM buthionine sulfoximine for 20
hr prior to chromate treatment; to increase cytochrome
P4SO, cells were treated with 10 mM isopentanol in the
presence or absence of 0.1 mM buthionine sulfoximine for 20
hr. After the isopentanol (with or without buthionine
sulfoximine) pretreatment, the medium was changed (with or
without buthionine sulfoximine) 1 hr prior to chromate
treatment, since isopentanol inhibits cytochrome P-450 acAbbreviation: GSH, glutathione.
tTo whom reprint requests should be addressed.
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tivity and this inhibition is removed by changing the medium
(J. Sinclair, personal communication).
Alkaline Elution. After sodium chromate treatment, the
hepatocytes were analyzed for DNA damage by using the
alkaline elution technique based on the procedure of Kohn et
al. (19) as described previously (6). The alkaline elution
technique measures the size distribution of long singlestranded DNA, assuming that the rate of elution of the DNA
from a polyvinylchloride filter depends on the length of the
DNA and is altered by filter absorption of proteins linked to
the DNA (19). DNA lesions were calculated from the DNA
remaining on the filter after 9 hr of elution, by using the
equations of Kohn et al. (19), and were based on the
comparison of DNA elution rates of control and treated cells
(with or without x-irradiation).
Assays for Cytochromes P-450. Cytochromes P-450 and
P-448 were determined by the CO difference spectral assay
(20). Benzphetamine-N-demethylase and 7-ethoxyresorufinO-deethylase activities, which are assays of cytochrome
P-450 and cytochrome P-448 isozymes, respectively, were
measured spectrofluorometrically in cell homogenates as
described previously (21).
GSH Assay. GSH was determined spectrofluorometrically
according to Hissin and Hilf (22) as described previously (6).
Up to 0.1 mM N-acetyl-L-cysteine did not interfere with this
assay.

Sodium Chromate Uptake. The uptake of chromium(VI) by
the hepatocytes was determined by analyzing the concentration of 51Cr remaining in the medium after a 2-hr treatment
with 5 ,uM sodium [51Cr]chromate (1 ,uCi/,ug).
Statistical Analysis. The Student t test was used for statistical analysis (23).

RESULTS
Alterations of Cellular GSH and Cytochrome P-450 Levels.
The effects of the various drug treatments on GSH and
cytochrome P-450 levels and activities in chicken embryo
hepatocytes are presented in Table 1. Since the cytochrome
P-450 level does not provide information on the specific
forms of cytochrome P-450 present, benzphetamine
demethylase and ethoxyresorufln deethylase activities,
which are specific for phenobarbital- and 3-methylcholan-
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threne-inducible isozymes, respectively, were determined.
None of the drug treatments changed the total amount of
protein found in the hepatocytes (0.40 ± 0.02 mg of protein
per 106 cells). After N-acetyl-L-cysteine treatment, GSH was
increased 80% while the cytochrome P450 concentration and
benzphetamine demethylase activity were unchanged. The
apparent decrease in ethoxyresorufin deethylase activity was
probably not significant since the levels in all treatments
except for f-naphthoflavone were close to the detection limit
(0.5 pmol of resorufin per mg of protein per min). Buthionine
sulfoximine treatment caused an 85% decrease in GSH levels
with no significant effect on cytochrome P-450 level or
activities. Since buthionine sulfoximine did not lower and
N-acetyl-L-cysteine did not increase benzphetamine
demethylase activity, cytochrome P-450 activity did not
depend on GSH concentration. Treatment of the hepatocytes
with isopentanol resulted in a 3.5-fold increase in cytoc';,-ome
P-450, associated with a 2-fold increase in benzphetamine
demethylase activity, and was accompanied by an 80%
increase in GSH. The combined treatment of isopentanol +
buthionine sulfoximine increased cytochrome P-450 3.5-fold
and benzphetamine demethylase activity 2-fold and decreased GSH 90%. After ,B-naphthoflavone treatment,
cytochrome P-448 was increased 2.5-fold with a 36-fold
increase in ethoxyresorufin deethylase activity without a
significant increase in benzphetamine demethylase activity
(P > 0.05) and GSH was decreased by 20% (P < 0.05). The
combined treatment of p-naphthoflavone + buthionine
sulfoximine increased cytochrome P-448 2-fold and
ethoxyresorufin activity 40-fold without any significant increase in benzphetamine demethylase activity (P > 0.05) and
it decreased GSH 85% (P < 0.001). GSH concentration did
not affect induced cytochrome P-450 activities since addition
of buthionine sulfoximine to the inducers isopentanol and
,B-naphthoflavone did not affect the benzphetamine demethylase or ethoxyresorufin deethylase activity. Addition of 5
,M sodium chromate for 2 hr after treatment of the
hepatocytes with the various drugs did not change GSH or
cytochrome P-450 levels or activities (P > 0.05). After
,3-naphthoflavone treatment, there was a 20% increase in
cytochrome P-448; however, there was no significant change
in ethoxyresorufin deethylase activity.

Table 1. Sodium [5tCr]chromate uptake, GSH, and cytochrome P-450 levels and enzymatic activities in chicken embryo hepatocytes after
treatment with various drugs with or without an additional 2-hr treatment with 5 uM sodium chromate
Benzphetamine
Ethoxyresorufin
demethylase,l
deethylase,1 pmol
Sodium
GSH,*t
Cytochrome P-450,*§
nmol HCHO per
resorufin per mg
[51Cr]chromate
% of control
pmol/mg protein
mg protein per hr
protein per min
uptake,*t
% 51Cr removed Without
With
Without
With
Without With Without With
from medium
Drug treatment
Cr(VI)
Cr(VI)
Cr(VI)
Cr(VI)
Cr(VI) Cr(VI) Cr(VI) Cr(VI)
No drug
34 3
100
94 ± 10 37 ± 3
32 ± 7
1.6
1.2
2.0
1.9
34 ± 1
N-Acetyl-L-cysteine
182 ± 19 197 ± 17
39 ± 3
44 ± 2
1.5
1.2
0.5
0.5
Isopentanol
37 ± 1
175 ± 22 193 ± 26 164 ± 20 154 ± 38
4.2
3.8
1.6
Isopentanol + buthionine
sulfoximine
36 1
8± 1
9 ± 2 170 ± 5 134 23
4.0
4.4
0.3
Buthionine sulfoximine
31 ± 2
12 ± 3
13 ± 2
29 ± 3
29 ± 3
1.6
1.2
1.4
1.3
33 ± 1
83 ± 8
80 ± 3 135 ± 5 159 ± 411
1.9
72
69
,3-Naphthoflavone
,3-Naphthoflavone + buthionine sulfoximine
35 ± 2
18
7
14
2 116 ± 16 103
4
2.3
82
53
*Values represent mean ± SEM for n 4.
tAll values are statistically the same (P > 0.1) vs. no drug treatment.
tGSH level in absence of drug treatment was 17 ± 3 nmol/mg of protein.
§Soret peak for no drug, N-acetyl-L-cysteine, buthionine sulfoximine, and isopentanol (with or without buthionine sulfoximine) is 450-452 nm
and for ,B-naphthoflavone (with or without buthionine sulfoximine) it is 449 nm.
$The error associated with duplicate values was - 20%.
IIP < 0.05 vs. no chromium(VI) treatment.
-
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Sodium Chromate-Induced DNA Strand Breaks. Treatment
of chicken embryo hepatocytes with 5 AM sodium chromate
for 2 hr resulted in 100 rad equivalents (1 rad = 0.01 gray) of
DNA strand breaks in the absence of proteinase K digestion
(Fig. 1). Upon proteinase K digestion of cell lysates, 140 rad
equivalents of protein-associated DNA strand breaks was
observed. Pretreatment of the hepatocytes with N-acetyl-Lcysteine, increasing GSH 80% with no change in cytochrome
P-450, was accompanied by a 50-80% increase in
chromium(VI)-induced DNA strand breaks (with or without
proteinase K). Isopentanol, which increased GSH 80% and
increased cytochrome P-450 3.5-fold, resulted in an approximately 140-170% increase in DNA strand breaks (with or
without proteinase K) caused by chromium(VI). After
isopentanol pretreatment the level of chromium(VI)-induced
strand breaks (with or without proteinase K) was 50-60%
greater than after N-acetyl-L-cysteine pretreatment (P <
0.02). Depletion of GSH with either an increase (isopentanol
+ buthionine sulfoximine treatment) or no change (buthionine sulfoximine treatment) in cytochrome P450 decreased
chromium(VI)-induced strand breaks approximately 50-75%
and completely eliminated protein-associated DNA strand
breaks. There was no significant difference between the
chromium(VI)-induced DNA strand breaks seen with
buthionine sulfoximine or buthionine sulfoximine +
isopentanol pretreatments (P > 0.1). Pretreatment of
hepatocytes with 83-naphthoflavone, which caused a 20%
decrease in GSH as well as a 2.5-fold increase in cytochrome
P-448, resulted in a 50-85% decrease in DNA strand breaks
caused by chromium(VI) and eliminated protein-associated
DNA strand breaks. Chromium(VI)-induced DNA strand
breaks were absent after the combined treatment of /3naphthoflavone + buthionine sulfoximine. This value was
significantly less than for buthionine sulfoximine or ,Bnaphthoflavone pretreatment alone (P < 0.01).
Sodium Chromate-Induced DNA Cross-Links. Chromium(VI)-induced DNA-protein and DNA interstrand crosslinks were affected less by varying cellular levels of
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FIG. 2. DNA cross-links in chicken embryo hepatocytes produced by chromium(VI) after various drug treatments. Cells were
treated as described in Fig. 1 legend. Open bars, total DNA
cross-links (without proteinase K digestion); cross-hatched bars,
DNA interstrand cross-links (with proteinase K digestion of the cell
lysates). Values represent mean ± SEM for n - 6.
*P < 0.01 vs. no drug treatment.
tP < 0.005 vs. no drug treatment.

cytochrome P-450 and GSH than were DNA strand breaks
(Fig. 2). DNA interstrand cross-links were not significantly
(P > 0.05) affected by changes in either cytochrome P-450 or
GSH levels except after the combined pretreatment with
/3-naphthoflavone + buthionine sulfoximine or isopentanol +
buthionine sulfoximine, which resulted in elimination of
DNA interstrand cross-links (P < 0.01). After isopentanol
pretreatment, the level of chromium(VI)-induced DNA
interstrand cross-links was greater than after N-acetyl-Lcysteine pretreatment (P < 0.05). Chromium(VI)-induced
total DNA cross-links (mainly DNA-protein cross-links)
were reduced approximately 50% (P < 0.005) by all the drug
treatments except isopentanol alone, with which no change
(P > 0.05) was observed.
Effect of Drug Treatments on Chromate Uptake. The uptake
of sodium chromate was measured after the various drug
U)
~~~~~~~~~~~~~t_
treatments to ensure that the changes in chromium(VI)~600induced DNA damage were not due to changes in
chromium(VI) uptake by the hepatocytes (Table 1). Expo-o
sure of hepatocytes to 5 ALM sodium chromate for 2 hr
resulted in removal of 31-37% of the [51Cr]chromate from the
medium under all pretreatment conditions. Thus, pretreatment with the drugs used in these experiments did not alter
-D0
(P > 0.1) the uptake of chromium(VI) by the cells.
Effect of Drug Treatments on DNA. For the effect of the
changes of GSH and cytochromes P-450 on chromium(VI)induced DNA damage to be measured accurately, the drugs
used to alter these cell constituents should not damage the
No Ac-Cys ISO ISO + BSO BNF BNF +
DNA. DNA damage resulting from the drug treatments is
BSO
BSO
drug
presented in Table 2. Little or no DNA damage was produced
Drug treatment
by the various drug treatments. Although buthionine
sulfoximine (with or without f3-naphthoflavone) pretreatment
FIG. 1. DNA strand breaks in chicken embryo hepatocytes
resulted in a small decrease in the amount of DNA strand
produced by chromium(VI) after various drug treatments. Cells were
breakage when analyzed in the absence of proteinase K,
pretreated with the indicated drugs and then exposed to 5 ,uM sodium
pretreatment with buthionine sulfoximine + isopentanol
chromate for 2 hr. Ac-Cys, N-acetyl-L-cysteine; ISO, isopentanol;
BSO, buthionine sulfoximine; BNF, /3-naphthoflavone. DNA strand
resulted in a slight increase in DNA strand breaks, and
breaks were measured by the alkaline elution technique, without
pretreatment with N-acetyl-L-cysteine caused no detectable
(open bars) or with (cross-hatched bars) proteinase K digestion.
change in DNA strand breaks. However, no DNA strand
Protein-associated strand breaks are represented by the difference
breaks
were observed under any condition upon proteinase K
between DNA strand breaks with and without proteinase K digestion
digestion. Thus, there does not appear to be any correlation
of the cell lysates. Calculations of DNA damage caused by
between GSH levels in the cells and DNA damage. fchromium(VI) treatment compared cells treated with drugs alone
Naphthoflavone (with or without buthionine sulfoximine)
with cells treated with chromium(VI) and drugs. Values represent
pretreatment resulted in a small amount of DNA cross-links
mean ± SEM for n - 6.
(mainly DNA-protein cross-links). In calculating the
*P < 0.01 vs. no drug treatment.
tp < 0.005 vs. no drug treatment.
chromium(VI)-induced DNA lesions, drug treatment plus
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Table 2. DNA damage in chicken embryo hepatocytes after various drug treatments
Strand breaks, rad equivalents
Cross-links, rad equivalents
Without
With
Without
With
proteinase K
proteinase K
proteinase K
proteinase K
Drug treatment
-3 ± 2
9 ± 10
-6 ± 8
14 ± 12
N-Acetyl-L-cysteine
Isopentanol
-32 ± 20
7 ± 30
-7 ± 11
-7 ± 35
15 ± 9
6± 7
6± 9
17 ± 7*
Isopentanol + buthionine sulfoximine
-2 ± 18
-1 ± 10
3± 7
-29 ± 8*
Buthionine sulfoximine
-27 ± 47
26 ± 6*
-11 ± 32
8 ± 15
3-Naphthoflavone
15 ± 9
19 ± 7*
-32 ± 36
-19 ± 9*
P-Naphthoflavone + buthionine sulfoximine
Cells were treated and analyzed for DNA damage by using alkaline elution. Calculations of DNA damage compared
untreated cells with drug-treated cells. All values represent mean ± SEM for n : 6.
*P < 0.05 vs. zero.

chromium(VI) treatment was always compared to drug treatment alone to eliminate any possible low level of DNA
damage resulting from the drug treatments from the data.

DISCUSSION
The level of chromium(VI)-induced DNA strand breaks was
dramatically increased in hepatocytes with increased levels
of GSH (N-acetyl-L-cysteine and isopentanol pretreatments)
and dramatically decreased with decreased levels of GSH
(buthionine sulfoximine and f3-naphthoflavone pretreatments) (Fig. 1). Increased levels of protein-associated DNA
strand breaks were observed only with treatments (N-acetylL-cysteine and isopentanol) that increased GSH levels. Protein-associated strand breaks may be due to chromium(VI)induced DNA-protein cross-links or to covalent attachment
of repair enzymes, topoisomerases, or other nuclear proteins
to sites of DNA strand breakage (24). These results suggest
that GSH played a key role in the activation of chromium(VI)
to species capable of causing DNA strand breaks. Although
GSH is usually thought to protect cells from the toxic effects
of agents such as acetaminophen (25), benzo[a]pyrene (26),
and radiation (27), it is also known to activate mutagens such
as N-hydroxy-3-amino-1-methyl-5H-pyrido[4,3-b]indole
(28), 1,2-dibromoethane (29, 30), 1,2-dichloroethane (31),
N-methyl- and N-ethyl-N'-nitro-N-nitrosoguanidine (29).
GSH has been shown to be important for reduction of
chromium(VI) in rat liver in vivo (14). GSH has been shown
to form a chromium(VI) thioester upon reaction with
chromium(VI) in vitro (12, 32). It is possible that formation of
a chromium(VI) thioester in cells could aid in the cellular
activation of chromium(VI). The chromium(VI) thioester of
GSH has been shown to undergo a redox reaction involving
GSH in vitro, producing reactive chromium(IV) species (12)
that may be capable of damaging DNA (Fig. 3). Even though
no change in GSH level was observed after chromium(VI)
treatment, the steady-state amount of the chromium(VI)
thioester in the cells is expected to be small (12), so the
detection of any small change in GSH levels is unlikely. Also,
previous studies have shown that chromium(VI) stimulates
the synthesis of GSH in chicken embryo hepatocytes (6).
GSH was not the only cellular metabolic system involved
in chromium(VI)-induced DNA damage. Induction of
cytochromes P-450 and P-448 also altered chromium(VI)induced DNA damage (Figs. 1 and 2). In the presence of high
levels of GSH, isopentanol-induced cytochrome P450 appeared to act synergistically with GSH and to increase the
chromium(VI)-induced DNA strand breaks (P < 0.01) and
DNA interstrand cross-links (P < 0.1). In the presence of
GSH, the level of chromium(VI)-induced DNA strand breaks
decreased after induction of cytochrome P-448 by ,Bnaphthoflavone. This could be due to the cytochrome P-448
deactivating the chromium(VI) or could be related to the 20%
decrease in GSH found upon /3-naphthoflavone treatment.

Also, f-naphthoflavone could have decreased other
cytochrome P-450 isozymes, such as the isozyme found in
control cells, which are capable of metabolizing chromium(VI). In chicken embryo liver, 3-naphthoflavone treatment decreases the level of the 2-allyl-2-isopropylacetamideinducible cytochrome P-450 mRNA below the normal level
found in untreated controls (34). When cellular GSH was
depleted by using buthionine sulfoximine, induction of
cytochrome P-450 or P-448 resulted in a dramatic decrease in
chromium(IV)-induced DNA damage. Under conditions of
high GSH, it is possible that cytochrome P-450 reacts with the
chromium(VI) thioester of GSH and forms species such as
chromium(IV) that can damage DNA (Fig. 3). Chromium(V)
species have been detected in vitro as intermediates in the
microsomal reduction of chromium(VI) (33) and in the
reaction of chromium(VI) with stoichiometric amounts of
GSH (32). Therefore, under conditions of low GSH and high
cytochrome P-450 or P-448, chromium(VI) may be metabolized to chromium(V) species, which are rapidly inactivated
within the cell (Fig. 3). It is also possible that these species
react with DNA to form adducts such as intrastrand crosslinks or monoadducts that are not detectable by the alkaline
elution technique.
The effect of GSH and cytochrome P-450 or P-448 on
chromium(VI)-induced DNA interstrand cross-links was
more difficult to detect than the effect on DNA strand breaks,
since the level of DNA interstrand cross-links was ½ to V5 of
the level of DNA strand breaks. However, high levels of
cytochrome P-450 or P-448 combined with low GSH resulted
in a detectable decrease in DNA interstrand cross-links. A
high level of cytochrome P-450 combined with high GSH
resulted in a detectable increase in DNA interstrand crosslinks compared with that seen under high GSH conditions.
A
GSH
CrO 2-

\

GSH
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FIG. 3. Possible metabolic pathways of chromium(VI) in'cells.
(A) Under conditions with high GSH levels. (B) Under conditions
with low GSH levels. GSSG, glutathione disulfide; GS-, glutathione
radical. See ref. 12 for the GSSG pathway in A and refs. 33 and 32,
respectively, for the cytochrome P-450 and GSH pathways in B.

Biochemistry: Cupo and Wetterhahn
These results were similar to those observed with chromium(VI)-induced DNA strand breaks.
Total DNA cross-links (mainly DNA-protein cross-links)
produced by chromium(VI) were not significantly changed by
the isopentanol pretreatment (high cytochrome P-450 with
high GSH). Both an increase and a decrease in GSH without
any change in cytochrome P-450 or P-448 resulted in a 40%
decrease in chromium(VI)-induced DNA-protein cross-links.
It appeared that DNA-protein cross-links may be formed by
a different mechanism than DNA strand breaks or DNA
interstrand cross-links. Chromium(V) intermediates or
chromium(III) complexes formed as the final products of
metabolism may be responsible for the formation of DNAprotein cross-links. It is possible that other cellular components such as GSH transferases may be involved in producing
some chromium(VI)-induced DNA lesions. Along with GSH,
GSH transferases have been shown to be important for the
formation of DNA adducts with 1,2-dibromoethane (30) and
N-hydroxy-3-amino-1-methyl-5H-pyrido[4,3-b]indole (28).
GSH transferases are altered in rats by 3-methylcholanthrene
and 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment (10). Another complication with the chromium(VI)-induced DNAprotein cross-links was that the level of cross-links might
have been rising at the time examined. Previous work with
chicken embryo hepatocytes has shown that chromium(VI)induced DNA-protein cross-links reached a maximal level 3
hr after removal of chromium(VI) following a 2-hr treatment
with 5 ptM chromium(VI) (6). In contrast, DNA interstrand
cross-links and strand breaks are maximal immediately after
the 2-hr chromium(VI) treatment (6).
In conclusion, certain forms of cytochrome P-450 in the
presence of GSH appeared to activate chromium(VI) to
species capable of producing DNA strand breaks and DNA
interstrand cross-links. However, upon depletion of GSH
and induction of cytochrome P-450 or P448 little or no
chromium(VI)-induced DNA strand breaks or interstrand
cross-links were observed. These studies indicate that GSH
might play a key role in chromium(VI) metabolism and
chromium(VI)-induced DNA damage, possibly through the
formation of a chromium(VI) thioester. Chromium(VI)-induced DNA-protein cross-links were decreased upon induction or depletion of GSH and were unchanged by cytochrome
P-450 in the presence of GSH, suggesting that these lesions
may be formed by a different mechanism than DNA strand
breaks and interstrand cross-links.
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